Sasanlimab (PF-06801591) is an investigational subcutaneously administered anti-PD-1 monoclonal antibody in development for bladder cancer and other solid tumors. Pfizer reported positive pivotal Phase 3 CREST data in BCG-naive high-risk non-muscle invasive bladder cancer and described plans for potential regulatory filings. It is not yet approved for marketing.
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07206225 |
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer |
RECRUITING | PHASE1 |
| NCT07123090 |
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma |
RECRUITING | PHASE2 |
| NCT06974734 |
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies |
TERMINATED | PHASE1 |
| NCT06870487 |
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers |
TERMINATED | PHASE1 |
| NCT06580938 |
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer |
TERMINATED | PHASE1 |
| NCT06546553 |
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. |
TERMINATED | PHASE1 |
| NCT06448364 |
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination |
TERMINATED | PHASE1 |
| NCT06285097 |
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors |
TERMINATED | PHASE1 |
| NCT06218069 |
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT05665361 |
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
RECRUITING | PHASE1/PHASE2 |
